Downregulation of miR‑362‑5p inhibits proliferation, migration and invasion of human breast cancer MCF7 cells

Ni,Fang; Gui,Zhaohua; Guo,Qiang; Hu,Zhongqian; Wang,Xinyi; Chen,Danlei; Wang,Siying

doi:10.3892/ol.2015.3993

Downregulation of miR‑362‑5p inhibits proliferation, migration and invasion of human breast cancer MCF7 cells

Authors:
- Fang Ni
- Zhaohua Gui
- Qiang Guo
- Zhongqian Hu
- Xinyi Wang
- Danlei Chen
- Siying Wang
View Affiliations

Affiliations: Department of Pathophysiology, Anhui Medical University, Hefei, Anhui 230032, P.R. China
Published online on: December 3, 2015 https://doi.org/10.3892/ol.2015.3993
Pages: 1155-1160

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

An increasing number of studies have indicated that the deregulation of microRNAs (miRNAs) contributes to tumorigenesis and metastasis. In the present study, significant upregulation of miR‑362‑5p was identified in the breast cancer MDA‑MB‑231 and MCF7 cell lines compared with the control CCD‑1095Sk cell line. The inhibition of miR‑362‑5p was demonstrated to significantly inhibit the cell proliferation, migration and invasion of human breast cancer MCF7 cells. In addition, the knockdown of miR‑362‑5p induced G1 arrest and promoted apoptosis in the breast cancer cells. Mechanistic investigations confirmed that the tumor suppressor gene CYLD is a direct target of miR‑362‑5p. The ectopic expression of miR‑362‑5p represses CYLD expression, whereas miR‑362‑5p inhibitor treatment induces CYLD protein expression and decreases NF‑κB expression in the downstream signaling pathway. Thus, these findings may provide novel insights into the molecular mechanisms through which miR‑362‑5p regulates breast cancer cell proliferation, migration and invasion. This study also suggests that miR‑362‑5p may act as a novel potential therapeutic target for the treatment of breast cancer.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
2	Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B and Senn HJ: Panel members: Strategies for subtypes - dealing with the diversity of breast cancer: Highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 22:1736–1747. 2011. View Article : Google Scholar : PubMed/NCBI
3	Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 98:10869–10874. 2001. View Article : Google Scholar : PubMed/NCBI
4	Giordano S and Columbano A: MicroRNAs: New tools for diagnosis prognosis, and therapy in HCC? Hepatology. 57:840–847. 2013. View Article : Google Scholar : PubMed/NCBI
5	Sanyal AJ, Yoon SK and Lencioni R: The etiology of hepatocellular carcinoma and consequences for treatment. Oncologist. 15(Suppl 4): 14–22. 2010. View Article : Google Scholar : PubMed/NCBI
6	El-Serag HB: Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 142:1264–1273.e1. 2012. View Article : Google Scholar : PubMed/NCBI
7	Kasinski AL and Slack FJ: Epigenetics and genetics. Histopathology. Nat Rev Cancer. 11:849–864. 2011. View Article : Google Scholar : PubMed/NCBI
8	Bartel DP: MicroRNAs: genomics biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
9	Dvinge H, Git A, Gräf S, Salmon-Divon M, Curtis C, Sottoriva A, Zhao Y, Hirst M, Armisen J, Miska EA, et al: The shaping and functional consequences of the microRNA landscape in breast cancer. Nature. 497:378–382. 2013. View Article : Google Scholar : PubMed/NCBI
10	Ebert MS and Sharp PA: Roles for microRNAs in conferring robustness to biological processes. Cell. 149:515–524. 2012. View Article : Google Scholar : PubMed/NCBI
11	Bignell GR, Warren W, Seal S, Takahashi M, Rapley E, Barfoot R, Green H, Brown C, Biggs PJ, Lakhani SR, et al: Identification of the familial cylindromatosis tumour-suppressor gene. Nat Genet. 25:160–165. 2000. View Article : Google Scholar : PubMed/NCBI
12	Kovalenko A, Chable-Bessia C, Cantarella G, Israël A, Wallach D and Courtois G: The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. Nature. 424:801–805. 2003. View Article : Google Scholar : PubMed/NCBI
13	Lim JH, Jono H, Komatsu K, Woo CH, Lee J, Miyata M, Matsuno T, Xu X, Huang Y, Zhang W, et al: CYLD negatively regulates transforming growth factor-beta-signalling via deubiquitinating Akt. Nat Commun. 3:7712012. View Article : Google Scholar : PubMed/NCBI
14	Tauriello DV, Haegebarth A, Kuper I, Edelmann MJ, Henraat M, Canninga-van Dijk MR, Kessler BM, Clevers H and Maurice MM: Loss of the tumor suppressor CYLD enhances Wnt/betacatenin signaling through K63-linked ubiquitination of Dvl. Mol Cell. 37:607–619. 2010. View Article : Google Scholar : PubMed/NCBI
15	Pannem RR, Dorn C, Ahlqvist K, Bosserhoff AK, Hellerbrand C and Massoumi R: CYLD controls c-MYC expression through the JNK-dependent signaling pathway in hepatocellular carcinoma. Carcinogenesis. 35:461–468. 2014. View Article : Google Scholar : PubMed/NCBI
16	Wang WY, Lim JH and Li JD: Synergistic and feedback signaling mechanisms in the regulation of inflammation in respiratory infections. Cell Mol Immunol. 9:131–135. 2012. View Article : Google Scholar : PubMed/NCBI
17	Gautheron J and Luedde T: A novel player in inflammation and cancer: The deubiquitinase CYLD controls HCC development. J Hepatol. 57:937–939. 2012. View Article : Google Scholar : PubMed/NCBI
18	Font-Burgada J, Seki E and Karin M: CYLD and HCC, When being too sensitive to your dirty neighbors results in self-destruction. Cancer Cell. 21:711–712. 2012. View Article : Google Scholar : PubMed/NCBI
19	Urbanik T, Köhler BC, Boger RJ, et al: Down-regulation of CYLD as a trigger for NF-κB activation and a mechanism of apoptotic resistance in hepatocellular carcinoma cells. Int J Oncol. 38:121–131. 2011.PubMed/NCBI
20	Hayashi M, Jono H, Shinriki S, et al: Clinical significance of CYLD downregulation in breast cancer. Breast Cancer Res Treat. 143:447–457. 2014. View Article : Google Scholar : PubMed/NCBI
21	Sun SC: CYLD: A tumor suppressor deubiquitinase regulating NF-kappaB activation and diverse biological processes. Cell Death Differ. 17:25–34. 2010. View Article : Google Scholar : PubMed/NCBI
22	Zhang W, Liu J and Wang G: The role of microRNAs in human breast cancer progression. Tumor Biol. 35:6235–6244. 2014. View Article : Google Scholar
23	Xia JT, Chen LZ, Jian WH, Wang KB, Yang YZ, He WL, He YL, Chen D and Li W: MicroRNA-362 induces cell proliferation and apoptosis resistance in gastric cancer by activation of NF-κB signaling. J Transl Med. 12:332014. View Article : Google Scholar : PubMed/NCBI
24	Chekulaeva M and Filipowicz W: Mechanisms of miRNA-mediated posttranscriptional regulation in animal cells. Curr Opin Cell Biol. 21:452–460. 2009. View Article : Google Scholar : PubMed/NCBI
25	Deng LL, Shao YX, Lv HF, Deng HB and Lv FZ: Over-expressing CYLD augments antitumor activity of TRAIL by inhibiting the NF-κB survival signaling in lung cancer cells. Neoplasma. 59:18–29. 2012. View Article : Google Scholar : PubMed/NCBI
26	Massoumi R: CYLD: A deubiquitination enzyme with multiple roles in cancer. Future Oncol. 7:285–297. 2011. View Article : Google Scholar : PubMed/NCBI